TORONTO–(BUSINESS WIRE)–The Ontario Bioscience Innovation Organization (OBIO®) and the City of Kawartha Lakes Family Health Team (CKL FHT) are launching a project in Ontario through OBIO’s Early Adopter Health Network (EAHN™) to improve the patient and provider experience, and enhance health outcomes via Goji Technology Systems’ innovative artificial intelligence (AI) virtual assistant platform, Goji Voice. … [Read more…]

LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #AlopeciaAreata—Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at The JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 p.m. ET in New York, NY. A webcast of the JMP fireside chat may be accessed in the Investors section of the Company’s website … [Read more…]

Strategic collaboration to further develop olamkicept highlights Ferring’s continued commitment to innovation in gastroenterology and inflammatory bowel disease. Olamkicept is the first and only clinical stage selective interleukin-6 (IL-6) inhibitor that works through the trans-signaling mechanism. IL-6 is associated with a number of inflammatory conditions, such as inflammatory bowel disease (IBD). SAINT-PREX, Switzerland–(BUSINESS WIRE)–#Ferring–Ferring Pharmaceuticals … [Read more…]

SAN FRANCISCO–(BUSINESS WIRE)–Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that it will participate in a webinar on Unlocking the Value of Digital Prescription Therapeutics hosted by Cowen to discuss the recently released promising pivotal clinical … [Read more…]

Annual Meeting of Stockholders rescheduled to Thursday, July 28, 2022, 8:30 a.m. ET CLEVELAND–(BUSINESS WIRE)–$ATHX–Athersys, Inc. (Nasdaq: ATHX) today announced the postponement of its Annual Meeting of Stockholders, initially scheduled for Wednesday, June 15, 2022, at 8:30 a.m. ET. The Annual Meeting is now scheduled for Thursday, July 28, 2022, at 8:30 a.m. ET. The … [Read more…]

– Cemdisiran Treatment Resulted in a 37 Percent Mean Reduction in 24-Hour Urine Protein to Creatinine Ratio, Relative to Placebo – a Key Prognostic Marker of Progression to End-Stage Kidney Disease in Patients with IgA Nephropathy – – Acceptable Safety Profile, Supporting Continued Clinical Development – – Full Results to Be Presented at Future Medical … [Read more…]

GARDENA, Calif.–(BUSINESS WIRE)–#SpectrumbioCERTIFIED—Spectrum Chemical Mfg. Corp. (“Spectrum Chemical”), a leading global provider of fine chemicals, laboratory equipment and supplies, has entered into a new distribution arrangement with ANGUS Chemical Company (“ANGUS”) that expands Spectrum Chemical’s product offerings for research and development and production scale-up at commercial and academic organizations serving the biopharmaceutical and life sciences … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Clinical Trials Sector Scorecard – Q1 2022 Update – Thematic Research” report has been added to ResearchAndMarkets.com’s offering. Many companies included in the Clinical Trials scorecard have announced partnerships in the artificial intelligence (AI) space since December 2021. Pfizer announced partnerships in drug discovery and disease severity scoring, while Thermo Fisher Scientific announced … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “South Africa Over-the-Counter (OTC) Healthcare Market Size by Categories, Distribution Channel, Market Share and Forecast, 2021-2026” report has been added to ResearchAndMarkets.com’s offering. The report on the OTC healthcare sector in South Africa provides insights on high growth markets to target, trends in the usage of category level distribution data and companies market … [Read more…]

Submission based on data from the pivotal international Phase III CONTENT clinical program, also recently published in European Urology1 CONTENT showed that Dysport® decreased incontinence episodes, detrusor pressure and increased bladder capacity versus placebo, and improved quality of life1 PARIS–(BUSINESS WIRE)–Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: … [Read more…]